

orthopedic procedures. Bone marrow transplantation has also been successfully performed. More recently enzyme replacement therapy has become available using a mannose terminated form human glucocerebrosidase. This therapy, often costing \$100,000 to \$300,000 per adult patient annually, has effectively improved biochemical and hematologic manifestations of this disorder in many patients and has reversed hepatosplenomegaly. The optimal dosing for this preparation is still under investigation. Also, other novel strategies for enzyme therapy and gene therapy for Gaucher disease are being actively pursued.

The purpose of this Technology Assessment Conference is to evaluate current concepts concerning diagnosis, genetic counseling, and management of Gaucher disease. The conference will bring together epidemiologists, geneticists, pediatricians, neurologists, obstetricians, orthopedists, hematologists, genetic counselors, clinical pathologists, others involved in health care delivery, as well as representatives of the public to review available data and make recommendations regarding population screening, genetic counseling, and current patient management as well as for future research.

After 1-1/2 days of presentations and audience discussion, an independent, non-Federal panel will weigh the scientific evidence and write a draft statement that it will present to the audience on the third day. The statement will address the following key questions:

What is the natural history of Gaucher disease and what is the appropriate technology to assess the severity and to predict the progression of this disorder?

What are the roles of current molecular and enzymatic assays for ascertaining affected individuals and carriers in various populations?

What are the indications for treatment of patients with Gaucher disease and what are the appropriate modes of therapy?

What are the goals for and consequences of treatment and how can the therapeutic interventions be assessed?

Under what circumstances could genotype/phenotype correlations be used for patient care and counseling?

What are the appropriate directions for future research?

The primary sponsors for this conference are the National Institute of Mental Health and the NIH Office of Medical Applications of Research. The conference is cosponsored by the

National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, the National Center for Research Resources, and the National Center for Human Genome Research.

Advance information on the conference program and conference registration materials may be obtained from: Debra DeBose, Technical Resources International, Inc., 3202 Tower Oaks Blvd., Suite 200, Rockville, Maryland 20852, (301) 770-3153.

The technology assessment statement will be submitted for publication in professional journals and other publications. In addition, the statement will be available beginning March 1, 1995 from the NIH Consensus Program Information Service, P.O. Box 2577, Kensington, Maryland 20891, phone 1-800-NIH-OMAR (1-800-644-6627).

Dated: February 10, 1995.

**Ruth L. Kirschstein,**

*Deputy Director, NIH.*

[FR Doc. 95-3991 Filed 2-16-95; 8:45 am]

BILLING CODE 4140-01-M

#### **National Heart, Lung, and Blood Institute; Notice of Meeting**

Pursuant to Pub. L. 92-463, notice is hereby given of the meetings of the following Heart, Lung, and Blood Special Emphasis Panels.

These meetings will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as a sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

*Name of Panel:* NHLBI SEP on Pulmonary Vascular Biology.

*Dates of Meeting:* March 9, 1995.

*Time of Meeting:* 8:00 a.m.

*Place of Meeting:* National Institutes of Health, Building 31C, Conference Room 8, Bethesda, Maryland.

*Agenda:* The panel will review the current status of research in the designated areas, identify gaps and make recommendations regarding opportunities and priorities for future contract or grant solicitations.

*Contact Person:* Dorothy B. Gail, Ph.D., 5333 Westbard Avenue, Room 6407, Bethesda, Maryland 20892, (301) 549-7428.

*Name of Panel:* NHLBI SEP on TB/AIDS.

*Dates of Meeting:* March 21, 1995.

*Time of Meeting:* 8:30 a.m.

*Place of Meeting:* National Institutes of Health, Natcher, Building 45, Conference Room C-1, Bethesda, Maryland 20892.

*Agenda:* The panel will review the current status of research in the designated areas,

identify gaps and make recommendations regarding opportunities and priorities for future contract or grant solicitations.

*Contact Person:* Hannah H. Peavy, M.D., 5333 Westbard Avenue, Room 6A09, Bethesda, Maryland 20892 (301) 594-7428.

*Name of Panel:* NHLBI SEP on Critical Care.

*Dates of Meeting:* March 28, 1995.

*Time of Meeting:* 8:30 a.m.

*Place of Meeting:* National Institutes of Health, Natcher, Building 45, Conference Room C-1, Bethesda, Maryland 20892.

*Agenda:* The panel will review the current status of research in the designated areas, identify gaps and make recommendations regarding opportunities and priorities for future contract or grant solicitations.

*Contact Person:* Carol H. Bosken, M.D., 5333 Westbard Avenue, Room 6A07, Bethesda, Maryland 20892, (301) 549-7428. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: February 9, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-3988 Filed 2-16-95; 8:45 am]

BILLING CODE 4140-01-M

#### **National Heart, Lung, and Blood Institute; Notice of a Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Demonstration and Education Research Applications.

*Date:* March 14-15, 1995.

*Time:* 9:00 a.m.

*Place:* Stouffer Concourse Hotel, Arlington, VA.

*Contact Person:* Dr. Louise Corman, 5333 Westbard Avenue, Room 548, Bethesda, MD 20892, (301) 594-7452.

*Purpose/Agenda:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)